Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07342868 · ClinicalTrials.gov registry record · Phase 1
Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function
A Phase 1 study of Chronic Hepaititis B Infections, sponsored by Aligos Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT07342868 is a Phase 1 study of Chronic Hepaititis B Infections that is actively recruiting participants, run by Aligos Therapeutics. The registered enrollment target is 16 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07342868, a Phase 1 study of Chronic Hepaititis B Infections, is actively recruiting participants, sponsored by Aligos Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
This Phase 1 non-randomized, open-label, single-dose hepatic impairment study consists of 2 cohorts, conducted in 16 subjects, 8 subjects with moderate hepatic impairment (Cohort 1) and 8 subjects without hepatic impairment (Cohort 2), matched for age, body weight and, to the extent possible, for sex. The effect of hepatic impairment on the plasma pharmacokinetics of ALG-001075 will be assessed in subjects who have received single oral doses of pevifoscorvir sodium (ALG-000184).
Conditions Studied
Interventions
- DRUG Pevifoscorvir Sodium (ALG-000184)
Study Locations (1)
Florida
- Orlando Clinical Research Center - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2026-01-30 |
| Est. Completion | 2026-05-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07342868
The ClinicalTrials.gov registry entry for NCT07342868 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aligos Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Hepaititis B Infections appearing as the primary indexed condition, and to 1 intervention - of which Pevifoscorvir Sodium (ALG-000184) is the first listed.
NCT07342868 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT07342868 about?
NCT07342868 is a clinical study titled "Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function". This Phase 1 non-randomized, open-label, single-dose hepatic impairment study consists of 2 cohorts, conducted in 16 subjects, 8 subjects with moderate hepatic impairment (Cohort 1) and 8 subjects without hepatic impairment (Cohort 2), matched for age, body weight and, to the extent possible, for se...
What is the current status of trial NCT07342868?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2026-01-30. Estimated completion is 2026-05-05.
What conditions does trial NCT07342868 study?
This clinical trial studies the following conditions: Chronic Hepaititis B Infections.
What interventions are being tested in trial NCT07342868?
The interventions under investigation include: Pevifoscorvir Sodium (ALG-000184) (DRUG).
Who is sponsoring clinical trial NCT07342868?
This trial is sponsored by Aligos Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07342868 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.